Berry Consultants

We need to run
Smarter Clinical Trials.

Success rates are falling.
Trial costs are increasing.
Patents worth billions of dollars are expiring.

Click to learn more
about the challenges facing pharma

Smarter Clinical Trials are vital

With ROI decreasing and drug therapies trending
towards more personalized care, the drug approval process
is in dire need of innovation.

Better Science
More Information per Dollar
Better Ethics

Learn How to Run
a Smarter Trial

Achieve your clinical trials
goals with us

Maximize the impact of your clinical trials on your
drug development process. Learn more

Ensure your trial answers the right questions
about your compound, cost-effectively
and on time. Learn more

Apply sophisticated trial design techniques
with total confidence. Learn more


Webinar Series

We run regular webinars that explore key issues in drug development and trial design.

Trial Design Centre

An adaptive Phase II trial may determine that subject enrolment can stop earlier than a traditional fixed length trial, or a trial with a fixed manually conducted interim. Stopping enrolment early can save considerable trial time and also money in reduced subject enrolment costs.

We have developed a spreadsheet to help you assess the possible impact of the approach on your trial and on your drug development programFind out more.

ROI Calculator

Expert Opinion

Tom Parke

Tom Parke

May 17, 2013

I-Spy 2 Trial

There’s a really interesting update on the progress of the I-Spy 2 trial here: http://www.onclive.com/publications/obtn/2013 Based on presentations at the 30th Annual Miami Breast Cancer Conference (MBCC) there’s more than usual about the disease and the treatments involved, but there’s also an update on how the different drugs in the trial are performing.

Tom Parke

Tom Parke

December 3, 2012

Krams: How to Popularize the Adaptive Approach

There has been some great coverage of Michael Krams’ talk that he gave at our Transforming Drug Development Conference http://www.innovationsinclinicaltrials.com/ Mike addressed the problems of developing treatments for Alzheimer’s and proposed some radical initiatives to address them. With a nice write up on Bio-IT World  http://www.bio-itworld.com, that has also been picked up by Fiercebiotech http://www.fiercebiotechit.com

Tom Parke

Tom Parke

November 12, 2012

The Simple Case for Saying Obama Is the Favorite

It’s not clinical trials, but the power of analytical prediction that has been gloriously demonstrated in the American presidential race http://fivethirtyeight.blogs.nytimes.com Nate Silver, the statistician behind 538, is a rare breed of statistician that knows how to communicate and is not afraid to do it. He not only has the nerve to make (fully statistically qualified) [...]



© Copyright 2013 Tessella plc | Sitemap | Cookie Policy